Alumis is a clinical-stage biopharmaceutical company developing targeted therapies for immune-mediated diseases. Its pipeline includes oral TYK2 inhibitors such as envudeucitinib for plaque psoriasis and systemic lupus erythematosus, plus a CNS-penetrant TYK2 program and lonigutamab for thyroid eye disease. The company uses a precision, data-driven approach from its base in South San Francisco.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 2.7 | — | 59.3 | — |
| Q3 2025 | 2.1 | — | -110.8 | — |
| Q4 2025 | 1.9 | — | -92.9 | — |
| Q1 2026 | 1.7 | — | -93 | — |
| Q2 2026 | 1.7 | -37.7% | -142.2 | -339.8% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Kelly Services, Inc. (KELYB), Independent Bank Corporation (IBCP), Barrett Business Services, Inc. (BBSI), Mako Mining Corp. (MAKO), Verastem, Inc. (VSTM), Root, Inc. (ROOT)